Clinical trials: Constipation - Functional
- Condition Constipation - Functional
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Constipation - Functional
Lubiprostone in Children With Functional Constipation
Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.
- Trial name
- NCT02042183
- Testing
- Lubiprostone
- Where
- 117 sites in United States, Belgium and 5 more
- Volunteers
- 606 people
- Sponsor
- Sucampo Pharma Americas, LLC
Functional Constipation, Irritable Bowel Syndrome With Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria…
- Trial name
- NCT04026113
- Testing
- Linaclotide
- Where
- 115 sites in United States, Belgium and 12 more
- Volunteers
- 438 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Functional Constipation
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility.
- Trial name
- NCT05760313
- Testing
- Linaclotide
- Where
- 38 sites in United States, Bulgaria and 5 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Joint Diseases, Arthritis
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week.
- Conditions
- Joint Diseases, Arthritis, Osteoarthritis
- Trial name
- NCT00784277
- Testing
- oxycodone CR, oxycodone IR, Tapentadol ER (CG5503)
- Volunteers
- 597 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility.
- Trial name
- NCT05652205
- Testing
- Linaclotide
- Where
- 48 sites in United States, Bulgaria and 2 more
- Volunteers
- 123 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH
Constipation
Dulcolax vs Placebo in Functional Constipation
The objective of the study was to compare the efficacy and safety of 4 weeks treatment with bisacodyl (Dulcolax) tablets 10 mg to placebo in patients with functional constipation.
- Trial name
- NCT00526097
- Testing
- Bisacodyl 10 mg
- Where
- 27 sites in United Kingdom
- Volunteers
- 368 people
- Sponsor
- Boehringer Ingelheim
Constipation
B. Lactis HN019 for Functional Constipation
This study will investigate the effects of 4-week probiotic supplementation on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
- Trial name
- CTT (NCT01463293)
- Testing
- B. lactis HN019
- Where
- 12 sites in United States
- Volunteers
- 224 people
- Sponsor
- Fonterra Research Centre
Functional Constipation
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
The purpose of this study is to evaluate the dose response, safety, and efficacy of linaclotide when compared with placebo in pediatric participants, 2 to 5 years of age, with Functional Constipation.
- Trial name
- NCT04110145
- Testing
- Linaclotide
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- Allergan
Functional Constipation
Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation.
- Trial name
- NCT02314936
- Testing
- Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose, Litesse powder containing 4 g polydextrose
- Where
- Canada
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Irritable Bowel Syndrome Characterized by Constipation
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00948818
- Testing
- Linaclotide 290 micrograms
- Where
- 118 sites in United States, Canada
- Volunteers
- 803 people
- Sponsor
- Forest Laboratories
Constipation
A Study of Prucalopride For Functional Constipation in Children and Teenagers
Functional constipation is a condition when it is very hard to pass a stool that is not due to any other health problem or to medicines being taken. This condition is more common in children and teenagers.
- Trial name
- NCT04759833
- Testing
- Prucalopride
- Where
- 41 sites in United States
- Volunteers
- 175 people
- Sponsor
- Takeda
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00399542
- Testing
- Lubiprostone
- Volunteers
- 581 people
- Sponsor
- Sucampo Pharma Americas, LLC